Company profile: Endogenex
1.1 - Company Overview
Company description
- Provider of an investigational endoscopic procedure (ReCET) that uses pulsed electric fields to regenerate signaling cells in the duodenum, aiming to improve blood glucose control in patients with type 2 diabetes.
Products and services
- Duodenal Signaling Cell Regeneration via Pulsed Electric Fields: Pulsed-electric technique that regenerates signaling cells in the duodenum to restore glucose regulation, targeting Type 2 Diabetes patients within a procedural workflow
- Endoscopic T2D Glycemic Control Procedure Development: Endogenex develops an endoscopic procedure to help Type 2 Diabetes patients regain blood glucose control by targeting duodenal signaling cells with pulsed electric fields
- ReCET Procedure: Investigational endoscopic procedure using pulsed electric fields to regenerate duodenal signaling cells, aiming to improve blood glucose control in patients with Type 2 Diabetes
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Endogenex
CureDM
HQ: United States
Website
- Description: Provider of biopharmaceutical therapies that may prevent, ameliorate or reverse diabetes, including Human proIslet Peptide (HIP), a novel human peptide developed to regenerate insulin-producing islets in the pancreas and potentially restore pancreatic function without stem cells, with the goal of allowing discontinuation of insulin.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CureDM company profile →
Satiogen
HQ: United States
Website
- Description: Provider of specialty pharmaceutical therapies targeting type 2 diabetes, offering metabolic mechanism therapy designed to regulate nutrient intake and postprandial glucose. Products include a substitute for metformin in gliptin formulations and an OTC nutraceutical.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Satiogen company profile →
Rubin Medical
HQ: Sweden
Website
- Description: Provider of diabetes aids for the public and healthcare sectors as a pharmaceutical company.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Rubin Medical company profile →
Diabetomics
HQ: United States
Website
- Description: Provider of non-invasive medical diagnostics for personalized health and diabetes risk, offering point-of-care tests: Glucema saliva test for diabetes monitoring via glycosylated proteins; Lumella blood test for early preeclampsia via glycosylated fibronectin; Insudex for early type-1 diabetes and LADA via autoantibody titers; RAprime for rheumatoid arthritis from oral fluid or finger stick; CovAb oral-swab COVID-19 antibody test detecting IgA/IgM/IgG.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Diabetomics company profile →
Dexcom
HQ: United States
Website
- Description: Provider of continuous glucose monitoring systems and data services for diabetes management, developing, manufacturing and distributing Dexcom G7 (real-time readings and alerts, compatible with Apple Watch), Dexcom G6 (for users 2+), and the OTC Stelo Glucose Biosensor System for adults not on insulin, plus Dexcom Clarity for glucose data analysis and Dexcom Follow/Share for remote data sharing.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Dexcom company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Endogenex
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Endogenex
2.2 - Growth funds investing in similar companies to Endogenex
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Endogenex
4.2 - Public trading comparable groups for Endogenex
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →